We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.91 surpassed the Zacks Consensus Estimate by 3.2%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 3.5%, on average.
Let’s check out the factors that have shaped BDX’s performance prior to this announcement.
Factors to Note Before BDX Reports
BD Life Sciences
BD Life Sciences’ performance in the second quarter of fiscal 2026 is expected to have remained under pressure, reflecting trends observed in the fiscal first quarter. In first-quarter fiscal 2026, the segment declined due to continued headwinds in both the Diagnostic Solutions and Biosciences businesses. Diagnostic Solutions’ performance was impacted by U.S. point-of-care headwinds, a difficult prior-year comparison and unfavorable market dynamics in China. Biosciences also faced pressure from lower life sciences research funding and tough comparisons to prior-year licensing revenues. These factors are likely to have persisted in the to-be-reported quarter, weighing on segmental revenues.
During the first quarter, BDX completed the spin-off and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to have influenced reported performance for the segment during the quarter.
The Zacks Consensus Estimate for second-quarter fiscal 2026 BD Life Sciences revenues is currently pegged at $372 million.
BD Interventional
BD Interventional’s momentum is expected to have continued into the second quarter of fiscal 2026, supported by strong performance across key growth platforms in the prior quarter. In first-quarter fiscal 2026, the segment delivered solid mid-single-digit growth, driven by high single-digit expansion in Urology & Critical Care, led by double-digit growth in the PureWick franchise, and continued strength in Peripheral Intervention, supported by oncology and peripheral vascular disease. Growth in the Surgery business was also robust, aided by strong performance in advanced tissue regeneration and infection prevention portfolios. These trends are likely to have persisted in the to-be-reported quarter, supporting segmental revenues.
During the quarter, BDX continued to advance its product portfolio with innovations in surgery and peripheral intervention, including expansion of the Surgiphor wound irrigation portfolio and CE marking for the Revello vascular covered stent in Europe. These developments are likely to have witnessed early adoption, contributing to growth in the to-be-reported quarter.
The Zacks Consensus Estimate for second-quarter fiscal 2026 BD Interventional revenues is currently pegged at $1.36 billion, suggesting an uptick of 7.4% from the year-ago quarter’s reported figure.
Other Factors to Note
BD Medical’s solid first-quarter fiscal 2026 performance is expected to have carried into the second quarter as key growth drivers likely remained intact. In the last reported quarter, the company witnessed broad-based growth across high-growth platforms, including double-digit expansion in biologic drug delivery within BioPharma Systems and pharmacy automation in Medication Management Solutions, along with high single-digit growth in advanced patient monitoring. Continued strength in GLP-1 and biologics demand, along with strong utilization trends in infusion sets, is likely to have supported performance in the to-be-reported quarter.
BDX’s Connected Care segment is also expected to have maintained momentum, driven by growth in pharmacy automation and advanced patient monitoring, including continued adoption of platforms like HemoSphere Alta and Smart Recovery. Additionally, ongoing demand for the BD Vacutainer portfolio within Specimen Management is likely to have supported segmental growth by improving workflow efficiency and diagnostic accuracy.
BD’s Estimate Picture
For second-quarter fiscal 2026, the Zacks Consensus Estimate for revenues is pegged at $4.67 billion, implying a decline of 11.5% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $2.77, indicating a decrease of 17.3% from the prior-year period’s reported number.
What Our Model Suggests About BDX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: BD has an Earnings ESP of -0.24%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Over the past three months, BD’s shares have lost 27.8%, underperforming the Medical - Dental Supplies’ 13.8% decline. BDX’s shares also underperformed the Zacks Medical sector’s decrease of 7.5% and the S&P 500’s growth of 6.9%.
Three Months Price Comparison
Image Source: Zacks Investment Research
BD’s peers, The Cooper Companies, Inc. (COO - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and McKesson Corporation (MCK - Free Report) have outperformed the company. COO, HSIC and MCK’s shares are down 21.5%, 3.1% and 14.9%, respectively, in the same time frame.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Can Sustained Product Momentum Drive BDX Stock Before Q2 Earnings?
Key Takeaways
Becton Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to report second-quarter fiscal 2026 results on May 7, before market open.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.91 surpassed the Zacks Consensus Estimate by 3.2%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 3.5%, on average.
Let’s check out the factors that have shaped BDX’s performance prior to this announcement.
Factors to Note Before BDX Reports
BD Life Sciences
BD Life Sciences’ performance in the second quarter of fiscal 2026 is expected to have remained under pressure, reflecting trends observed in the fiscal first quarter. In first-quarter fiscal 2026, the segment declined due to continued headwinds in both the Diagnostic Solutions and Biosciences businesses. Diagnostic Solutions’ performance was impacted by U.S. point-of-care headwinds, a difficult prior-year comparison and unfavorable market dynamics in China. Biosciences also faced pressure from lower life sciences research funding and tough comparisons to prior-year licensing revenues. These factors are likely to have persisted in the to-be-reported quarter, weighing on segmental revenues.
During the first quarter, BDX completed the spin-off and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to have influenced reported performance for the segment during the quarter.
The Zacks Consensus Estimate for second-quarter fiscal 2026 BD Life Sciences revenues is currently pegged at $372 million.
BD Interventional
BD Interventional’s momentum is expected to have continued into the second quarter of fiscal 2026, supported by strong performance across key growth platforms in the prior quarter. In first-quarter fiscal 2026, the segment delivered solid mid-single-digit growth, driven by high single-digit expansion in Urology & Critical Care, led by double-digit growth in the PureWick franchise, and continued strength in Peripheral Intervention, supported by oncology and peripheral vascular disease. Growth in the Surgery business was also robust, aided by strong performance in advanced tissue regeneration and infection prevention portfolios. These trends are likely to have persisted in the to-be-reported quarter, supporting segmental revenues.
During the quarter, BDX continued to advance its product portfolio with innovations in surgery and peripheral intervention, including expansion of the Surgiphor wound irrigation portfolio and CE marking for the Revello vascular covered stent in Europe. These developments are likely to have witnessed early adoption, contributing to growth in the to-be-reported quarter.
The Zacks Consensus Estimate for second-quarter fiscal 2026 BD Interventional revenues is currently pegged at $1.36 billion, suggesting an uptick of 7.4% from the year-ago quarter’s reported figure.
Other Factors to Note
BD Medical’s solid first-quarter fiscal 2026 performance is expected to have carried into the second quarter as key growth drivers likely remained intact. In the last reported quarter, the company witnessed broad-based growth across high-growth platforms, including double-digit expansion in biologic drug delivery within BioPharma Systems and pharmacy automation in Medication Management Solutions, along with high single-digit growth in advanced patient monitoring. Continued strength in GLP-1 and biologics demand, along with strong utilization trends in infusion sets, is likely to have supported performance in the to-be-reported quarter.
BDX’s Connected Care segment is also expected to have maintained momentum, driven by growth in pharmacy automation and advanced patient monitoring, including continued adoption of platforms like HemoSphere Alta and Smart Recovery. Additionally, ongoing demand for the BD Vacutainer portfolio within Specimen Management is likely to have supported segmental growth by improving workflow efficiency and diagnostic accuracy.
BD’s Estimate Picture
For second-quarter fiscal 2026, the Zacks Consensus Estimate for revenues is pegged at $4.67 billion, implying a decline of 11.5% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $2.77, indicating a decrease of 17.3% from the prior-year period’s reported number.
What Our Model Suggests About BDX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: BD has an Earnings ESP of -0.24%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company price-eps-surprise | Becton, Dickinson and Company Quote
BD’s Share Price Performance
Over the past three months, BD’s shares have lost 27.8%, underperforming the Medical - Dental Supplies’ 13.8% decline. BDX’s shares also underperformed the Zacks Medical sector’s decrease of 7.5% and the S&P 500’s growth of 6.9%.
Three Months Price Comparison
Image Source: Zacks Investment Research
BD’s peers, The Cooper Companies, Inc. (COO - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and McKesson Corporation (MCK - Free Report) have outperformed the company. COO, HSIC and MCK’s shares are down 21.5%, 3.1% and 14.9%, respectively, in the same time frame.